Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-03-20
2007-03-20
Kemmerer, Elizabeth (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C436S501000
Reexamination Certificate
active
10460623
ABSTRACT:
The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4710473 (1987-12-01), Morris
patent: 4959314 (1990-09-01), Mark et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5393739 (1995-02-01), Bentz et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5457035 (1995-10-01), Baum et al.
patent: 5578569 (1996-11-01), Tam
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5599708 (1997-02-01), Mundy et al.
patent: 5658756 (1997-08-01), Rodan et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5843901 (1998-12-01), Roeske
patent: 5985832 (1999-11-01), Roodman et al.
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6087555 (2000-07-01), Dunstan et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6242586 (2001-06-01), Gorman et al.
patent: 6271349 (2001-08-01), Dougall et al.
patent: 6284485 (2001-09-01), Boyle et al.
patent: 6284728 (2001-09-01), Boyle et al.
patent: 6284740 (2001-09-01), Boyle et al.
patent: 6288032 (2001-09-01), Boyle et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6369027 (2002-04-01), Boyle et al.
patent: 6419929 (2002-07-01), Anderson
patent: 6525180 (2003-02-01), Gorman et al.
patent: 6528482 (2003-03-01), Anderson et al.
patent: 6537763 (2003-03-01), Dougall et al.
patent: 6562948 (2003-05-01), Anderson
patent: 6649164 (2003-11-01), Maraskovsky
patent: 6740522 (2004-05-01), Anderson et al.
patent: 7097834 (2006-08-01), Boyle
patent: 2002/0081720 (2002-06-01), Dougall et al.
patent: 2002/0086826 (2002-07-01), Anderson et al.
patent: 2002/0086827 (2002-07-01), Anderson
patent: 2002/0127637 (2002-09-01), Ni et al.
patent: 2002/0150989 (2002-10-01), Greene et al.
patent: 2002/0169117 (2002-11-01), Maraskovsky
patent: 2003/0100069 (2003-05-01), Ni et al.
patent: 2003/0100488 (2003-05-01), Boyle
patent: 2003/0103978 (2003-06-01), Deshpande et al.
patent: 2003/0104485 (2003-06-01), Boyle
patent: 2003/0144480 (2003-07-01), Gorman et al.
patent: 2003/0166097 (2003-09-01), Greene et al.
patent: 2003/0175840 (2003-09-01), Anderson et al.
patent: 2004/0023313 (2004-02-01), Boyle et al.
patent: 2004/0033535 (2004-02-01), Boyle et al.
patent: 56180/98 (1998-07-01), None
patent: 68518/98 (1998-11-01), None
patent: 71205/98 (1998-11-01), None
patent: 0 514 130 (1992-11-01), None
patent: 0514130 (1992-11-01), None
patent: 0 526 905 (1993-02-01), None
patent: 0 526 905 (1993-02-01), None
patent: 0727211 (1996-08-01), None
patent: 0 874 045 (1998-10-01), None
patent: 0 911 342 (1999-04-01), None
patent: 330400 (1999-05-01), None
patent: 86/00922 (1986-02-01), None
patent: 90/14363 (1990-11-01), None
patent: 93/12227 (1993-06-01), None
patent: 93/21946 (1993-11-01), None
patent: 95/11308 (1995-04-01), None
patent: 96/26217 (1996-08-01), None
patent: 96/28546 (1996-09-01), None
patent: 97/00317 (1997-01-01), None
patent: 97/00318 (1997-01-01), None
patent: 97/23614 (1997-07-01), None
patent: 98/07840 (1998-02-01), None
patent: 98/25958 (1998-06-01), None
patent: 98/28246 (1998-07-01), None
patent: 98/28424 (1998-07-01), None
patent: 98/28426 (1998-07-01), None
patent: 98/46644 (1998-10-01), None
patent: 98/46751 (1998-10-01), None
patent: 98/49305 (1998-11-01), None
patent: 98/54201 (1998-12-01), None
patent: 99/19468 (1999-04-01), None
patent: 99/53942 (1999-10-01), None
patent: 99/58674 (1999-11-01), None
patent: 99/58674 (1999-11-01), None
patent: 01 03719 (2001-01-01), None
patent: 01 03719 (2001-01-01), None
patent: 01 17543 (2001-03-01), None
patent: 01 17543 (2001-03-01), None
patent: 01 18203 (2001-03-01), None
patent: 03 002713 (2003-01-01), None
Adams et al. “Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project”,Science, 252: 1651-1656 (1991).
Anderson et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function”,Nature, 390:175-179 (1997).
Chambers et al., “Generation of osteoclast-inductive and osteosclastogenic cell lines from theH-2KbtsA58transgenic mouse”,Proceedings of the National Academy of Sciences of USA, 90:5578-5582 (1993).
Fawthrop et al., “The Effect of Transforming Growth Factor β on the Plasminogen Activator Activity of Normal Human Osteoblask-like Cells and a Human Osteosarcoma Cell Line MG-63”,Journal of Bone and Mineral Research, 7(12):1363-1371 (1992).
Fenton et al., “Long-Term Culture of Disaggregated Rat Osteoclasts: Inhibition of Bone Resorption and Reduction of Osteoclast-like Cell Number by Calcitonin and PTHrP[107-139]”,Journal of Cellular Physiology, 155:1-7 (1993).
George et al., “Current Methods in Sequence Comparison and Analysis”,Macromolecular Sequencing and Synthesis Selected Methods and Applications, pp. 127-149 (1988).
Goodwin et al., “Molecular Cloning Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor”,Molecular and Cellular Biology, 11(6):3020-3026 (1991).
Gowen et al., “Preferential Inhibition of Cytokine-Stimulated Bone Resorption by Recombinant Interferon Gamma”,Journal of Bone and Mineral Research, 1(5):469-474 (1986).
Hattersley et al., “Human Macrophage Colony-Stimulating Factor Inhibits Bone Resorption by Osteoclasts Disaggregated From Rat Bone”,Journal of Cellular Physiology, 137:199-203 (1988).
International Search Report, International Application No. PCT/JP98/01728 (1998).
Kaji et al., “Insuline-Like Growth Factor-I Mediates Osteoclast-Like Cell Formation Stimulated by Parathyroid Hormone”,Journal of Cellular Physiology, 172:55-62 (1997).
Kasono et al., “Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture”,Bone and Mineral, 21(3):179-188 (1993).
Kukita et al., “Osteoinductive factor inhibits formation of human osteoclast-like cells”,Proceedings of the National Academy of Sciences of USA, 87:3023-3026 (1990).
Lewis et al., “Cloning and expression of cDNAS for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific”,Proceedings of the National Academy of Sciences of USA, 88:2830-2834 (1991).
Reedi, A. H., “Bone Morphogenesis and Modeling: Soluble Signals Sculpt Osteosomes in the Solid State”,Cell, 89:159-161 (1997).
Rieger et al.,Glossary of Genetics and Cytogenetics, p. 17, Springer-Verlag, Berlin Heidlberg, New York (1976).
Simonet et al., “Osteoprotegerin: A Novel Secreted Protein Involed in the Regulation of Bone Density”,Cell, 89:309-319 (1997).
Smith et al., “The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death”,Cell, 76:959-962 (1994).
Suda et al., “Modulation of Osteoclast Differentiation by Local Factors”,Bone, 17(2 Suppl):87S-91S (1995).
Takada et al., “A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells”,Bone and Mineral, 17:347-359 (1992).
Tsuda et al., “Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis”,Biochemical and Biophysical Research Communications, 234(1):137-142 (1997).
Watanabe et al.,
Goto Masaaki
Higashio Kanji
Kinosaki Masahiko
Kobayashi Fumie
Morinaga Tomonori
Arnold & Porter LLP
Kemmerer Elizabeth
Sankyo Co. Ltd
LandOfFree
Methods for identifying a substance which specifically binds... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying a substance which specifically binds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying a substance which specifically binds... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3739587